Articles From: Endocyte to Present at the Future Leaders in the Biotech Industry Conference to Energen Announces 1st Quarter 2013 Earnings Release Date, Conference Call

WEST LAFAYETTE, Ind., April 1, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) , a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that Ron Ellis, president and CEO of Endocyte, will present at the Future Leaders in the Biotech Industry Conference on Friday, April 5, at 2:30 p.m. EDT.

WEST LAFAYETTE, Ind., Feb.

WEST LAFAYETTE, Ind., Feb.

WEST LAFAYETTE, Ind., March 18, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) , a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced the company's management team will host an Investor and Analyst Day on Friday, March 22, 2013, from 9:30 a.m. to 1 p.m. EDT at The Setai Fifth Avenue in New York City.

WEST LAFAYETTE, Ind., April 22, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) , a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that it will hold its 2013 Annual Meeting of Stockholders on Wednesday, June 19 in Indianapolis.

Patients With 100 Percent Folate Receptor-Positive Tumor Lesions Experienced Substantial Progression-Free Survival When Treated With Vintafolide SAN DIEGO, March 1, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) , a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced a new analysis demonstrating that the investigational diagnostic imaging agent etarfolatide (EC20) can identify ovarian cancer and non-small cell lung cancer (NSCLC) patients who could benefit from folate receptor-targeted therapeutics, such as the novel investigational cancer candidate vintafolide (MK-8109/EC145). Patients with all target tumor lesions positive as assessed by etarfolatide imaging, FR(100%) experienced substantial progression-free survival (PFS) compared to patients with 10 to 90 percent of target lesions positive for folate receptor,

IRVINE, Calif., April 16, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) , developer and marketer of innovative treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval of its premarket approval (PMA) supplement for a broadened indication for the Company's 21Fr profile and smaller EVAR systems to include totally percutaneous endovascular aneurysm repair (PEVAR) based upon the outcomes of the first prospective, multicenter, randomized clinical trial (The PEVAR Trial). The Endologix EVAR platforms include the Powerlink ® with IntuiTrak® System and the AFX™ Endovascular AAA System, which are the first and only among commercially available endografts to achieve the totally percutaneous labeling expansion facilitated using the Perclose ProGlide ® Suture-Mediated Closure System made by healthcare company Abbott.

IRVINE, Calif., April 15, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) , developer and marketer of innovative treatments for aortic disorders, announced today that Roderick de Greef will retire from the Board of Directors at the end of his current term, which ends on May 23, 2013, the date of the Company's annual shareholder meeting.

Provides Update on New Product Pipeline Including Enhancements to Ventana Program That Will Delay IDE Enrollment and Limited Market Introduction in Europe IRVINE, Calif., April 30, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) , developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2013 and provided an update on the company's new product pipeline.

IRVINE, Calif., Feb.

IRVINE, Calif., May 8, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) , developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate in three upcoming investor conferences in May and June.

IRVINE, Calif., March 11, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) , developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer and Shelley Thunen, Chief Financial Officer, are scheduled to present at the 25th Annual ROTH Conference in Laguna Niguel, CA.

IRVINE, Calif., April 8, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) , developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2013 financial results, which will take place on Tuesday, April 30, 2013 after the close of the market.

IRVINE, Calif., Feb.

Enduro Royalty Trust (NYSE: NDRO) (the “Trust”) announced today a cash distribution to the holders of its units of beneficial interest of $0.070519 per unit, payable on March 14, 2013, to unitholders of record on February 28, 2013.

Enduro Royalty Trust (NYSE: NDRO) (the “Trust”) announced today a cash distribution to the holders of its units of beneficial interest of $0.056553 per unit, payable on April 12, 2013, to unitholders of record on March 28, 2013.

Enduro Royalty Trust (NYSE: NDRO) (the “Trust”) announced today a cash distribution to the holders of its units of beneficial interest of $0.124518 per unit, payable on May 14, 2013, to unitholders of record on April 30, 2013.

Enel Green Power SpA (EGPW.MI), one of Europe's biggest renewables companies by market value, Tuesday said it expects core profits to rise in the next five years as it expands into electricity-hungry emerging markets.

Italian utility Enel SpA (ENEL.MI) Tuesday said first-quarter net profit fell 26% on the year as recessions in its key Italian and Spanish markets took their toll, although the drop was smaller than expected thanks to strong renewable energy earnings.

Italian utility Enel SpA (ENEL.MI) Tuesday said first-quarter net profit fell 26% on the year as recessions in its key Italian and Spanish markets took their toll, although the drop was smaller than expected thanks to strong renewable energy earnings.

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0849673001&sourceType=1 http://www.ccnmatthews.com/logos/20110103-Enercare200.jpg http://media3.marketwire.com/docs/enercaresol_200.jpg TORONTO, ONTARIO --

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0866190001&sourceType=1 http://www.ccnmatthews.com/logos/20110103-Enercare200.jpg TORONTO, ONTARIO --

PRESENTING COMPANIES: 12 U.S. E&P AND OILSERVICE COMPANIES AVERAGE ENTERPRISE VALUE: $4.4 BILLION DENVER , May 6, 2013 /PRNewswire/ --  EnerCom, Inc. today announced its presentation line-up for the London Oil & Gas Conference™ 5 at the Sofitel London St.

Agenda: 24 Public E&P Companies, 9 Public OilService Companies, and 10 Thought Leaders DENVER , Feb.

Agenda: 24 Public E&P Companies, 9 Public OilService Companies, and 10 Thought Leaders DENVER , Feb.

DENVER , Feb.

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0867642001&sourceType=1 http://www.ccnmatthews.com/logos/20110601-enerflex.jpg CALGARY, ALBERTA --

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0869158001&sourceType=1 http://www.ccnmatthews.com/logos/20110601-enerflex.jpg CALGARY, ALBERTA --

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0856401005&sourceType=1 http://www.ccnmatthews.com/logos/20110601-enerflex.jpg CALGARY, ALBERTA --

Energen Corporation (NYSE: EGN) today announced that it plans to issue its 1 st quarter 2013 earnings release on Monday, April 29, 2013, before trading begins on the New York Stock Exchange.